Detall de la convocatòria

Característiques

Característica
Objectiu de la convocatòria
TRANSCAN-2 has the goal of coordinating national and regional funding programmes for research in the area of translational cancer research. The specific challenge is to promote a transnational collaborative approach between scientific teams in demanding areas of translational cancer research while avoiding the duplication of efforts and ensuring a more efficient use of available resources, to produce significant results of higher quality and impact, and share data and infrastructures.
The EC co-funded call of TRANSCAN-2 (JTC 2016) will focus on: “Minimally and non-invasive methods for early detection and/or progression of cancer”
Minimally invasive methods refer to techniques that have limited physical damage, burden and pain associated with the detection method, resulting in less anticipated stress, a higher screening/clinical care uptake, and more efficient and cost-effective screening and care. The studied methods should be sensitive for early detection of cancer, its staging and prediction of progression. Examples are: individual or combination of molecular, immunochemical, proteomic or genetic markers in body fluids and blood or cell samples, as well as macroscopic, microscopic and molecular imaging techniques (e.g. improved ultrasound technology, molecular imaging with contrast agents, fluorescence imaging, radiolabelling).
This call excludes invasive methods, such as image-guided biopsy or surgery.
Característiques principals
In the context of translational cancer research, this topic will comprise three specific aims. Proposals will have to cover at least one of the specific areas listed under each undermentioned aim.

  • Aim 1: Risk stratification to distinguish groups by susceptibility for development or progression of cancer based on molecular biomarkers and established cancer risk factors, such as age, medical history, anthropometrics (e.g., body mass index, waist circumference), and lifestyle related determinants (e.g., diet, physical exercise, environmental exposure and medication).
  • Aim 2: Validation of multiparametric methods, using the combination of promising[1] biomarkers (genomic, proteomic, metabolomic and imaging markers) to improve our capability for early detection or progression of cancer.
  • Aim 3: Improve clinical evidence of the minimally invasive methods.

    The following types of research projects are excluded from the call:
    1. Analysis of preclinical models (cell lines and animal models) only.
    2. Phase III and IV clinical trials.
    3. Studies not compliant with the COMMISSION REGULATION (EC) No 800/2008 (link), with specific reference to the articles 30, 31, 32, and 33. For full reference, please see also the COMMUNICATION FROM THE COMMISSION TO THE EUROPEAN PARLIAMENT, THE COUNCIL, THE EUROPEAN ECONOMIC AND SOCIAL COMMITTEE AND THE COMMITTEE OF THE REGIONS of 20.12.2011. Studies not compliant with the Commission Regulation (EU) No 651/2014 of 17 June 2014. Please check the call text for additional information.
    • Lloc de presentació
    El personal de l'IMIM i PSMAR que necessiteu més informació adreceu-vos a:
    Servei de Recerca. C/ Doctor Aiguader, 88. 08003-Barcelona. Tel.: 93.316.04.00.
    Carol Barnwell: cbarnwell@imim.es Ext.: 1670
    Marta López: mlopez4@imim.es Ext.: 1576
    Convocatòria (URL)
    http://www.transcanfp7.eu/calls/third-joint-transnational-call-jtc-2016.html
    Informació addicional
    Aplicatiu web:
    https://secure.pt-dlr.de/ptoutline/app/transcan_2016
    (Online submission will be possible from 2nd January 2017).
    Requisits
    Only transnational projects will be funded. Each research consortium must involve a minimum of three (3) research groups and a maximum of seven (7) research groups. The groups must be from at least three (3) different countries participating in the call. In addition, a consortium must not involve more than two (2) research groups from one country (in such cases the minimum number of groups must be 4, coming from 3 different countries). The maximum number of 7 research groups could be increased only with partners from the following countries : Estonia, Latvia and Slovakia, up to a maximum of 3 additional partners from the 3 countries, to reach a maximum total of 10 research groups in a proposal.

    In order to strengthen the European translational cancer research area, a wide inclusion of research teams from all the countries/regions participating in the call is encouraged, with a particular attention to research teams from Estonia, Latvia, Slovakia.

    Each consortium must involve at least one basic or pre-clinical research team and one clinical team.

    Plase check the Call Text for detailed eligibility rules.

    For Spanish applicants: please check the eligibility requirements of the institution and the principal investigator/team members, in pages 56-59 of the Call Text.
    Dotació
    For Spanish participants:
  • up to 200,000 € (overheads included) per partner
  • up to 300.000 € (overheads included) per coordinator
    • Durada
    3 years
    AVÍS IMPORTANT
    En cas de voler presentar-vos a la convocatòria, per favor no contacteu directament amb ISCIII/AECC, dirigiu-vos al Servei de Recerca (Carol Barnwell / Marta López).

    Arxius

    Arxiu
    Call text
    Pre-proposal Application Form
    Guidelines for Applicants
    National Contact Points